Search

Author/Creator Dehlendorff, C.

1. 776TiPPACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. (18th September 2017)

Authors:
Chen, I.; Johansen, J.S.; Zimmers, T.A.; Dehlendorff, C.; Kirk Parner, V.; Vittrup Jensen, B.; Nielsen, D.
Journal:
Annals of oncology
Issue:
Volume 28(2017)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. SAT0016 Microrna Expression Profiles as Biomarkers for Prediction of Treatment Response to Adalimumab in Patients with Early Rheumatoid Arthritis. (23rd January 2014)

Authors:
Krintel, S. B.; Dehlendorff, C.; Hetland, M. L.; Hørslev-Petersen, K.; Andersen, K. K.; Junker, P.; Pødenphant, J.; Ellingsen, T.; Ahlqvist, P.; Lindegaard, H. M.; Linauskas, A.; Schlemmer, A.; Dam, M. Y.; Hansen, I.; Horn, H. C.; Jørgensen, A.; Raun, J.; Ammitzbøll, C. G.; Østergaard, M.; Stenga...
Journal:
Annals of the rheumatic diseases
Issue:
Volume 72:Supplement 3(2013)
Page Start:
A584
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗